CRMP2–Neurofibromin Interface Drives NF1-related Pain

Aubin Moutal, Li Sun, Xiaofang Yang, Wennan Li, Song Cai, Shizhen Luo, Rajesh Khanna

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

An understudied symptom of the genetic disorder Neurofibromatosis type 1 (NF1) is chronic idiopathic pain. We used targeted editing of Nf1 in rats to provide direct evidence of a causal relationship between neurofibromin, the protein product of the Nf1 gene, and pain responses. Our study data identified a protein-interaction network with collapsin response meditator protein 2 (CRMP2) as a node and neurofibromin, syntaxin 1A, and the N-type voltage-gated calcium (CaV2.2) channel as interaction edges. Neurofibromin uncouples CRMP2 from syntaxin 1A. Upon loss/mutation of neurofibromin, as seen in patients with NF1, the CRMP2/Neurofibromin interaction is uncoupled, which frees CRMP2 to interact with both syntaxin 1A and CaV2.2, culminating in increased release of the pro-nociceptive neurotransmitter calcitonin gene-related peptide (CGRP). Our work also identified the CRMP2-derived peptide CNRP1, which uncoupled CRMP2's interactions with neurofibromin, syntaxin 1A, as well as CaV2.2. Here, we tested if CRISPR/Cas9-mediated editing of the Nf1 gene, which leads to functional remodeling of peripheral nociceptors through effects on the tetrodotoxin-sensitive (TTX-S) Na+ voltage-gated sodium channel (NaV1.7) and CaV2.2, could be affected using CNRP1, a peptide designed to target the CRMP2–neurofibromin interface. The data presented here shows that disrupting the CRMP2–neurofibromin interface is sufficient to reverse the dysregulations of voltage-gated ion channels and neurotransmitter release elicited by Nf1 gene editing. As a consequence of these effects, the CNRP1 peptide reversed hyperalgesia to thermal stimulation of the hindpaw observed in Nf1-edited rats. Our findings support future pharmacological targeting of the CRMP2/neurofibromin interface for NF1-related pain relief.

Original languageEnglish (US)
Pages (from-to)79-90
Number of pages12
JournalNeuroscience
Volume381
DOIs
StatePublished - Jun 15 2018

Fingerprint

Semaphorin-3A
Neurofibromin 1
Neurofibromatosis 1
Syntaxin 1
Neurofibromatosis 1 Genes
Pain
Neurofibromin 2
Proteins
NAV1.7 Voltage-Gated Sodium Channel
Peptides
Neurotransmitter Agents
Clustered Regularly Interspaced Short Palindromic Repeats
Protein Interaction Maps
Nociceptors
Inborn Genetic Diseases
Calcitonin Gene-Related Peptide
Hyperalgesia
Tetrodotoxin
Calcium Channels
Ion Channels

Keywords

  • CaV2.2
  • CRMP2
  • NaV1.7
  • Neurofibromatosis type 1
  • neurofibromin
  • pain

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

CRMP2–Neurofibromin Interface Drives NF1-related Pain. / Moutal, Aubin; Sun, Li; Yang, Xiaofang; Li, Wennan; Cai, Song; Luo, Shizhen; Khanna, Rajesh.

In: Neuroscience, Vol. 381, 15.06.2018, p. 79-90.

Research output: Contribution to journalArticle

Moutal A, Sun L, Yang X, Li W, Cai S, Luo S et al. CRMP2–Neurofibromin Interface Drives NF1-related Pain. Neuroscience. 2018 Jun 15;381:79-90. https://doi.org/10.1016/j.neuroscience.2018.04.002
Moutal, Aubin ; Sun, Li ; Yang, Xiaofang ; Li, Wennan ; Cai, Song ; Luo, Shizhen ; Khanna, Rajesh. / CRMP2–Neurofibromin Interface Drives NF1-related Pain. In: Neuroscience. 2018 ; Vol. 381. pp. 79-90.
@article{1616a6f60eed4f718e5aa25ae9cd540b,
title = "CRMP2–Neurofibromin Interface Drives NF1-related Pain",
abstract = "An understudied symptom of the genetic disorder Neurofibromatosis type 1 (NF1) is chronic idiopathic pain. We used targeted editing of Nf1 in rats to provide direct evidence of a causal relationship between neurofibromin, the protein product of the Nf1 gene, and pain responses. Our study data identified a protein-interaction network with collapsin response meditator protein 2 (CRMP2) as a node and neurofibromin, syntaxin 1A, and the N-type voltage-gated calcium (CaV2.2) channel as interaction edges. Neurofibromin uncouples CRMP2 from syntaxin 1A. Upon loss/mutation of neurofibromin, as seen in patients with NF1, the CRMP2/Neurofibromin interaction is uncoupled, which frees CRMP2 to interact with both syntaxin 1A and CaV2.2, culminating in increased release of the pro-nociceptive neurotransmitter calcitonin gene-related peptide (CGRP). Our work also identified the CRMP2-derived peptide CNRP1, which uncoupled CRMP2's interactions with neurofibromin, syntaxin 1A, as well as CaV2.2. Here, we tested if CRISPR/Cas9-mediated editing of the Nf1 gene, which leads to functional remodeling of peripheral nociceptors through effects on the tetrodotoxin-sensitive (TTX-S) Na+ voltage-gated sodium channel (NaV1.7) and CaV2.2, could be affected using CNRP1, a peptide designed to target the CRMP2–neurofibromin interface. The data presented here shows that disrupting the CRMP2–neurofibromin interface is sufficient to reverse the dysregulations of voltage-gated ion channels and neurotransmitter release elicited by Nf1 gene editing. As a consequence of these effects, the CNRP1 peptide reversed hyperalgesia to thermal stimulation of the hindpaw observed in Nf1-edited rats. Our findings support future pharmacological targeting of the CRMP2/neurofibromin interface for NF1-related pain relief.",
keywords = "CaV2.2, CRMP2, NaV1.7, Neurofibromatosis type 1, neurofibromin, pain",
author = "Aubin Moutal and Li Sun and Xiaofang Yang and Wennan Li and Song Cai and Shizhen Luo and Rajesh Khanna",
year = "2018",
month = "6",
day = "15",
doi = "10.1016/j.neuroscience.2018.04.002",
language = "English (US)",
volume = "381",
pages = "79--90",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - CRMP2–Neurofibromin Interface Drives NF1-related Pain

AU - Moutal, Aubin

AU - Sun, Li

AU - Yang, Xiaofang

AU - Li, Wennan

AU - Cai, Song

AU - Luo, Shizhen

AU - Khanna, Rajesh

PY - 2018/6/15

Y1 - 2018/6/15

N2 - An understudied symptom of the genetic disorder Neurofibromatosis type 1 (NF1) is chronic idiopathic pain. We used targeted editing of Nf1 in rats to provide direct evidence of a causal relationship between neurofibromin, the protein product of the Nf1 gene, and pain responses. Our study data identified a protein-interaction network with collapsin response meditator protein 2 (CRMP2) as a node and neurofibromin, syntaxin 1A, and the N-type voltage-gated calcium (CaV2.2) channel as interaction edges. Neurofibromin uncouples CRMP2 from syntaxin 1A. Upon loss/mutation of neurofibromin, as seen in patients with NF1, the CRMP2/Neurofibromin interaction is uncoupled, which frees CRMP2 to interact with both syntaxin 1A and CaV2.2, culminating in increased release of the pro-nociceptive neurotransmitter calcitonin gene-related peptide (CGRP). Our work also identified the CRMP2-derived peptide CNRP1, which uncoupled CRMP2's interactions with neurofibromin, syntaxin 1A, as well as CaV2.2. Here, we tested if CRISPR/Cas9-mediated editing of the Nf1 gene, which leads to functional remodeling of peripheral nociceptors through effects on the tetrodotoxin-sensitive (TTX-S) Na+ voltage-gated sodium channel (NaV1.7) and CaV2.2, could be affected using CNRP1, a peptide designed to target the CRMP2–neurofibromin interface. The data presented here shows that disrupting the CRMP2–neurofibromin interface is sufficient to reverse the dysregulations of voltage-gated ion channels and neurotransmitter release elicited by Nf1 gene editing. As a consequence of these effects, the CNRP1 peptide reversed hyperalgesia to thermal stimulation of the hindpaw observed in Nf1-edited rats. Our findings support future pharmacological targeting of the CRMP2/neurofibromin interface for NF1-related pain relief.

AB - An understudied symptom of the genetic disorder Neurofibromatosis type 1 (NF1) is chronic idiopathic pain. We used targeted editing of Nf1 in rats to provide direct evidence of a causal relationship between neurofibromin, the protein product of the Nf1 gene, and pain responses. Our study data identified a protein-interaction network with collapsin response meditator protein 2 (CRMP2) as a node and neurofibromin, syntaxin 1A, and the N-type voltage-gated calcium (CaV2.2) channel as interaction edges. Neurofibromin uncouples CRMP2 from syntaxin 1A. Upon loss/mutation of neurofibromin, as seen in patients with NF1, the CRMP2/Neurofibromin interaction is uncoupled, which frees CRMP2 to interact with both syntaxin 1A and CaV2.2, culminating in increased release of the pro-nociceptive neurotransmitter calcitonin gene-related peptide (CGRP). Our work also identified the CRMP2-derived peptide CNRP1, which uncoupled CRMP2's interactions with neurofibromin, syntaxin 1A, as well as CaV2.2. Here, we tested if CRISPR/Cas9-mediated editing of the Nf1 gene, which leads to functional remodeling of peripheral nociceptors through effects on the tetrodotoxin-sensitive (TTX-S) Na+ voltage-gated sodium channel (NaV1.7) and CaV2.2, could be affected using CNRP1, a peptide designed to target the CRMP2–neurofibromin interface. The data presented here shows that disrupting the CRMP2–neurofibromin interface is sufficient to reverse the dysregulations of voltage-gated ion channels and neurotransmitter release elicited by Nf1 gene editing. As a consequence of these effects, the CNRP1 peptide reversed hyperalgesia to thermal stimulation of the hindpaw observed in Nf1-edited rats. Our findings support future pharmacological targeting of the CRMP2/neurofibromin interface for NF1-related pain relief.

KW - CaV2.2

KW - CRMP2

KW - NaV1.7

KW - Neurofibromatosis type 1

KW - neurofibromin

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=85046764436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046764436&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2018.04.002

DO - 10.1016/j.neuroscience.2018.04.002

M3 - Article

C2 - 29655575

AN - SCOPUS:85046764436

VL - 381

SP - 79

EP - 90

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -